SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD 2000 Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 85: 31093115.
  • 2
    Ettinger B, San Martin J, Crans G, Pavo I 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19: 745751.
    Direct Link:
  • 3
    Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 11891199.
  • 4
    Lenart BA, Lorich DG, Lane JM 2008 Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358: 13041306.
  • 5
    Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG 2008 Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22: 346350.
  • 6
    Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS 2007 Subtrochanteric insufficiency fractures in patients on alendronate therapy: A caution. J Bone Joint Surg Br 89: 349353.
  • 7
    Kwek EB, Goh SK, Koh JS, Png MA, Howe TS 2008 An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy ? Injury 39: 224231.
  • 8
    Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P 2008 Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev CD001155.
  • 9
    Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH 1999 The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 46: 263268.
  • 10
    Concato J, Shah N, Horwitz RI 2000 Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342: 18871892.
  • 11
    Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P 2008 Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev CD001155.
  • 12
    Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY 2005 Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 90: 12941301.
  • 13
    Hundrup YA, Hoidrup S, Obel EB, Rasmussen NK 2004 The validity of self-reported fractures among Danish female nurses: Comparison with fractures registered in the Danish National Hospital Register. Scand J Public Health 32: 136143.
  • 14
    Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG 2008 Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22: 346350.
  • 15
    Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Brookhart MA 2005 Compliance with osteoporosis medications. Arch Intern Med 165: 24142419.
  • 16
    Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81: 10131022.
  • 17
    Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA 2005 Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43: 11301139.
  • 18
    Schneeweiss S, Wang PS, Avorn J, Glynn RJ 2003 Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res 38: 11031120.
  • 19
    Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M 2007 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. Epidemiology 18: 805835.